New Options and Combinations in Diabetes Management: Optimizing Control and Individualizing Treatment

Thursday, September 8, 2016 | 6:00-8:00 PM PST
Washington State Convention Center, Room 6AB

This course is a live CME-certified ancillary symposium presented at Clinical Endocrinology Update 2016, held in Seattle, Washington, September 8-10, 2016. CEU 2016 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC).

This activity is supported by an educational grant from Novo Nordisk Inc.

Anne Peters, MD – Program Director
Professor of Medicine
Director, USC Westside Center for Diabetes
University of Southern California
Los Angeles, CA

David Kayne, MD
Physician
Medical Group of Encino
Encino, CA

Janet McGill, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Carol Wysham, MD
Physician
Rockwood Clinic
Spokane, WA

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Select and start GLP-1 receptor agonist therapy taking patient considerations and differential glycemic effects into account
  • Integrate basal insulins into the early management of appropriate patients with type 2 diabetes taking into consideration the efficacy and safety profiles of new formulations
  • Use updated clinical information on emerging insulin/GLP-1 receptor agonist combinations to individualize treatment plans for patients with type 2 diabetes

Additional Information

AttachmentSize
Program Materials2.77 MB
Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Quality Improvement and Healthcare Delivery
General Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
09/08/2016
Course expires: 
09/08/2017
Rating: 
0
San Francisco, CA
United States

Anne Peters, MD – Program Director
Professor of Medicine
Director, USC Westside Center for Diabetes
University of Southern California
Los Angeles, CA

David Kayne, MD
Physician
Medical Group of Encino
Encino, CA

Janet McGill, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Carol Wysham, MD
Physician
Rockwood Clinic
Spokane, WA

Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Anne L. Peters, MD: Advisory Board Member/Consultant, Abbott Diabetes Care, Becton Dickinson, Bigfoot Biomedical, Biodel, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC, CVS/Caremark, Astra-Zeneca, Intarcia, Janssen Pharmaceuticals, Lexicon, Medtronic-Minimed, Merck & Co. Inc., Novo Nordisk Inc., Omada Health, OptumRx, Thermalin; Research Funding, Janssen Pharmaceuticals, Medtronic Foundation; Editorial Fees, Medscape

David Kayne, MD: Research Support, AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi; Speaker, AstraZeneca/BMS, Boehringer Ingelheim, Eli Lilly, Insulet, Janssen, Mannkind, Novo Nordisk, Sanofi

Janet B. McGill, MD: Consultant, Boehringer Ingelheim Pharmaceuticals, Inc. & Lilly USA, LLC, Calibra Medical, Merck & Co. Inc.; Consultant and Speaker, Janssen Pharmaceuticals; Consultant and Research Funding, Novo Nordisk Inc.; Research Funding, Dexcom, Inc., Lexicon Pharmaceuticals, Inc., Novartis Pharmaceuticals

Carol Wysham, MD: Advisor, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, sanofi; Consultant, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Novo Nordisk, sanofi; Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Insulet, Janssen, Novo Nordisk, sanofi

The following SPC member who planned and reviewed content for this activity reported no financial relationships: Amy Rothberg, MD

The following SPC Committee members reported financial relationships:

Zahid Ahmad, MD: Consultant, Regeneron; Speaker, Amgen, Genzyme, Sanofi
Andrew Ahmann, MD: Research Support, DexCom, Lexicon Medtronic, Novo Nordisk, Sanofi Aventis; Consultant, Novo Nordisk, Eli Lilly, Janssen, Dexcom
John Carmichael, MD: Research Support, Novo Nordisk, Chiasma, Novartis, Pfizer, Strongbridge Biopharma; Speaker, Novartis; Advisory Board, Pfizer, Chiasma, Ionis Pharmaceuticals
Alan Kelly, MD: Research Support, Novo Nordisk; Speaker, Novo Nordisk, Boehringer Ingelheim
E Michael Lewiecki, MD: Advisory Board, Amgen, Merck, Eli Lilly, Radius Health, Shire, and Alexion; Speaker, Shire; Research Grant Support, Amgen, Eli Lilly, MerckLisa Nachtigall, MD: Consultant, Pfizer, Chiasma
Neda Rasouli, MD: Research Support, Novo Nordisk, Calibra, INTARCIA Therapeutics, GlaxoSmithKline, Bristol Meyer Squibb, AstraZeneca /Amylin, Ionis Pharmaceuticals, Boehringer Ingelheim, Pfizer

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Giuseppe Barbesino, MD; Natalie Cusano, MD; Joan Han, MD; Connie Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation

Accreditation Period

Course opens: 
09/08/2016
Course expires: 
09/08/2017